Design and Synthesis of Some New Quinoline-thiazolidine-2,4-dione-isoxazole Conjugates as EGFR Targeting Agents

IF 0.9 4区化学 Q4 CHEMISTRY, MULTIDISCIPLINARY

Russian Journal of General Chemistry Pub Date : 2024-08-30 DOI:10.1134/S1070363224070193

K. Swapna, N. Satheesh Kumar, N. Malla Reddy, M. Ravinder

{"title":"Design and Synthesis of Some New Quinoline-thiazolidine-2,4-dione-isoxazole Conjugates as EGFR Targeting Agents","authors":"K. Swapna, N. Satheesh Kumar, N. Malla Reddy, M. Ravinder","doi":"10.1134/S1070363224070193","DOIUrl":null,"url":null,"abstract":"A series of new quinoline-thiazolidine-2,4-dione-isoxazole conjugates was synthesized and evaluated for in vitro anticancer potency against two breast cancer cell lines, such as MCF-7, MDA-MB231, and the normal cancer cell line MCF-10 A (breast cell line) using erlotinib as a standard drug. (Z)-3-{[5-(4-Methoxyphenyl)isoxazol-3-yl]methyl}-5-(quinolin-4-ylmethylene)thiazolidine-2,4-dione and (Z)-3-{[5-(3,5-dimethoxyphenyl)isoxazol-3-yl]methyl}-5-(quinolin-4-ylmethylene)thiazolidine-2,4-dione showed higher anticancer activities against two cancer cell lines, with IC50 ranging from 3.10 ± 0.43, 2.01 ± 0.03, 3.04 ± 0.05, and 2.00 ± 0.07 μM. Furthermore, (Z)-3-{[5-(4-methoxyphenyl)isoxazol-3-yl]methyl}-5-(quinolin-4-ylmethylene)thiazolidine-2,4-dione, and (Z)-3-{[5-(3,5-dimethoxyphenyl)isoxazol-3-yl]methyl}-5-(quinolin-4-ylmethylene)thiazolidine-2,4-dione displayed more inhibitory activity over tyrosine kinase EGFR when compared with the standard erlotinib.","PeriodicalId":761,"journal":{"name":"Russian Journal of General Chemistry","volume":"94 7","pages":"1758 - 1767"},"PeriodicalIF":0.9000,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Russian Journal of General Chemistry","FirstCategoryId":"92","ListUrlMain":"https://link.springer.com/article/10.1134/S1070363224070193","RegionNum":4,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 0

Abstract

A series of new quinoline-thiazolidine-2,4-dione-isoxazole conjugates was synthesized and evaluated for in vitro anticancer potency against two breast cancer cell lines, such as MCF-7, MDA-MB231, and the normal cancer cell line MCF-10 A (breast cell line) using erlotinib as a standard drug. (Z)-3-{[5-(4-Methoxyphenyl)isoxazol-3-yl]methyl}-5-(quinolin-4-ylmethylene)thiazolidine-2,4-dione and (Z)-3-{[5-(3,5-dimethoxyphenyl)isoxazol-3-yl]methyl}-5-(quinolin-4-ylmethylene)thiazolidine-2,4-dione showed higher anticancer activities against two cancer cell lines, with IC₅₀ ranging from 3.10 ± 0.43, 2.01 ± 0.03, 3.04 ± 0.05, and 2.00 ± 0.07 μM. Furthermore, (Z)-3-{[5-(4-methoxyphenyl)isoxazol-3-yl]methyl}-5-(quinolin-4-ylmethylene)thiazolidine-2,4-dione, and (Z)-3-{[5-(3,5-dimethoxyphenyl)isoxazol-3-yl]methyl}-5-(quinolin-4-ylmethylene)thiazolidine-2,4-dione displayed more inhibitory activity over tyrosine kinase EGFR when compared with the standard erlotinib.

Abstract Image

查看原文本刊更多论文

作为表皮生长因子受体靶向药物的新型喹啉-噻唑烷-2,4-二酮-异恶唑共轭物的设计与合成

摘要合成了一系列新的喹啉-噻唑烷-2,4-二酮-异恶唑共轭物，并以厄洛替尼为标准药物，评估了它们对 MCF-7、MDA-MB231 等两种乳腺癌细胞系和正常癌细胞系 MCF-10 A（乳腺癌细胞系）的体外抗癌效力。(Z)-3-{[5-(4-甲氧基苯基)异恶唑-3-基]甲基}-5-(喹啉-4-基亚甲基)噻唑烷-2,4-二酮和(Z)-3-{[5-(3,5-二甲氧基苯基)异恶唑-3-基]甲基}-5-(喹啉-4-基亚甲基)噻唑烷-2,4-二酮对两种癌细胞株显示出较高的抗癌活性，IC50 分别为 3.10 ± 0.43、2.01 ± 0.03、3.04 ± 0.05 和 2.00 ± 0.07 μM。此外，与标准药物厄洛替尼相比，(Z)-3-{[5-（4-甲氧基苯基）异噁唑-3-基]甲基}-5-（喹啉-4-基亚甲基）噻唑烷-2,4-二酮和(Z)-3-{[5-（3,5-二甲氧基苯基）异噁唑-3-基]甲基}-5-（喹啉-4-基亚甲基）噻唑烷-2,4-二酮对酪氨酸激酶表皮生长因子受体具有更强的抑制活性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Russian Journal of General Chemistry 化学-化学综合

CiteScore

1.40

自引率

22.20%

发文量

252

审稿时长

2-4 weeks

期刊介绍： Russian Journal of General Chemistry is a journal that covers many problems that are of general interest to the whole community of chemists. The journal is the successor to Russia’s first chemical journal, Zhurnal Russkogo Khimicheskogo Obshchestva (Journal of the Russian Chemical Society ) founded in 1869 to cover all aspects of chemistry. Now the journal is focused on the interdisciplinary areas of chemistry (organometallics, organometalloids, organoinorganic complexes, mechanochemistry, nanochemistry, etc.), new achievements and long-term results in the field. The journal publishes reviews, current scientific papers, letters to the editor, and discussion papers.